Clinical Trial: Phase 3 Trial of Resmetirom Versus Placebo in Metabolic Dysfunction-Associated Steatohepatitis-Reanalysis of Fibrosis Stage 2-3 Subset [0.03%]
resmetirom治疗代谢性肝病临床试验：含2-3期非酒精性脂肪性肝炎患者的亚组分析
Maria Mironova,Krishna Padmanabhan,David Schneider et al.
Maria Mironova et al.
Background: Resmetirom is an oral thyroid hormone receptor beta agonist clinically used to treat metabolic dysfunction-associated steatohepatitis (MASH) among adults with stage F2 or F3 fibrosis. ...
Letter: Frail, Not Forgotten: Closing the Loop Between Geriatric Assessment and IBD Care [0.03%]
致编辑：脆弱，未被遗忘：老年评估与IBD治疗之间的闭环护理
Thomas M Strobel,Dhyanesh A Patel,Robin L Dalal
Thomas M Strobel
Editorial: A New Insert Device for Faecal Incontinence-To Use or Not to Use? Author's Reply [0.03%]
编辑来信：一种新的粪失禁器械——用还是不用？作者回应
Adil E Bharucha
Adil E Bharucha
Review Article: Accelerating Coeliac Disease Clinical Trials-Beyond Celiac Meeting With Industry, Academics, Patients and the FDA [0.03%]
加速乳糜泻临床试验的评审文章：超越乳糜泻与工业、学术界、患者和美国食品药品监督管理局的会议
Lisa M Fahey,Robert Anderson,Edwin Liu et al.
Lisa M Fahey et al.
Background: Coeliac disease is due to an acquired, lifelong gluten-specific immune response resulting in a gluten-dependent chronic immune-mediated enteropathy associated with gastrointestinal and extraintestinal morbidit...
Letter: Interpretation of Cognitive and Clinical Outcomes in the Randomized Trial of Rifaximin for Covert Hepatic Encephalopathy. Authors' Reply [0.03%]
利福昔明治疗隐性肝性脑病随机对照试验的认知和临床结果的解读：作者回复
Hiroki Inada,Yasuhito Tanaka
Hiroki Inada
Clinical Trial: Multi-Strain Probiotic Improves Bile Acid Profile, Microbiome, and Metabolomic Parameters in Patients With History of Bile Acid Malabsorption-A Randomized, Controlled Trial [0.03%]
临床试验：多菌株益生菌可改善胆汁酸缺乏症患者的胆汁酸轮廓、微生物组和代谢参数-一项随机对照试验
John A Damianos,Ayah Matar,Paula Carlson et al.
John A Damianos et al.
Background: Bile acid (BA) malabsorption (BAM) is a common cause of chronic diarrhoea and may occur in some patients due to abnormalities of the gut microbiota. Effects of probiotics on faecal secretory BAs, particularly ...
Letter: Major Adverse Outcomes in Steatotic Liver Disease Subtypes-From Etiological Classification to Biological Phenotyping [0.03%]
来信：根据病因分类到生物分型的脂肪肝亚型的主要不良结局
Annalisa Cespiati,Jörn M Schattenberg
Annalisa Cespiati
Editorial: A New Insert Device for Faecal Incontinence-To Use or Not to Use? [0.03%]
editorial：该用来治疗大便失禁还是不用？新的置入装置究竟是福音还是诅咒？
Aditya Ashok,Kyle Staller
Aditya Ashok